BioPharma Dive May 10, 2021
Moderna and BioNTech weren’t exactly household names before last year. But their research into messenger RNA quickly came into the spotlight as the coronavirus spread around the world. Now, many countries’ best chance at ending the pandemic lies with the effective vaccines these companies developed.
Against this backdrop, the biotechnology incubator that founded Moderna launched on Monday another company focused on the therapeutic potential of RNA, the single-stranded courier of genetic information. The company, Laronde, comes equipped with $50 million in funding from Flagship Pioneering and a lofty goal to upend how diseases are treated, through the use of so-called eRNA, or endless RNA.
In cells, messenger RNA provides the instructions for what proteins need to be made. These instructions...
Today's Sponsors
Today's Sponsor